The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

Australian specialists, scientists and researchers are at the forefront of treatments that could change the lives of people ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Chase Coleman’s commitment to identifying high-quality businesses, especially in the tech sector, is reflected in Tiger ...

Recent pharmaceutical innovations have opened a new path for weight loss through drugs based on gut hormones such as GLP-1 ...